REATA PHARMACEUTICALS INC·4

Jun 9, 4:28 PM ET

Castellanos Elaine 4

4 · REATA PHARMACEUTICALS INC · Filed Jun 9, 2021

Insider Transaction Report

Form 4
Period: 2021-06-07
Transactions
  • Conversion

    Class A common stock

    2021-06-07+1,54616,092 total
  • Sale

    Class A common stock

    2021-06-09$141.86/sh7,900$1,120,68815,100 total
  • Conversion

    Class B common stock

    2021-06-071,5460 total
    Class A common stock (1,546 underlying)
  • Exercise/Conversion

    Class B common stock

    2021-06-09$22.57/sh+8,454$190,8078,454 total
    Class A common stock (8,454 underlying)
  • Sale

    Class A common stock

    2021-06-09$142.50/sh554$78,94314,546 total
  • Exercise/Conversion

    Class B common stock

    2021-06-07$22.57/sh+1,546$34,8931,546 total
    Class A common stock (1,546 underlying)
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-06-098,4549,934 total
    Exercise: $22.57Exp: 2026-12-07Class B common stock (8,454 underlying)
  • Conversion

    Class B common stock

    2021-06-098,4540 total
    Class A common stock (8,454 underlying)
  • Sale

    Class A common stock

    2021-06-07$146.47/sh910$133,28715,182 total
  • Conversion

    Class A common stock

    2021-06-09+8,45423,000 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-06-071,54618,388 total
    Exercise: $22.57Exp: 2026-12-07Class B common stock (1,546 underlying)
  • Sale

    Class A common stock

    2021-06-07$147.16/sh636$93,59514,546 total
Footnotes (6)
  • [F1]The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $146.05 to $146.94. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $147.09 to $147.255. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $141.25 to $142.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $142.43 to $142.71. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F6]The options vest in twenty equal quarterly installments beginning on March 7, 2017, subject to continued service through each vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION